Vir Biotechnology, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
Vir Biotechnology, Inc. (VIR) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$1.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-05
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was -$1.72M.
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was -$170.00K, a 102.66% decline year-over-year.
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$2.61M.
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $1.33M, a 18.14% increase year-over-year.
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $1.73M.
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$5.53M.
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$21.89M.
- Vir Biotechnology, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$111.14M, a 180.51% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.72M 10-Q · filed 2026-08-05 | -$1.89M 10-Q · filed 2026-08-05 | -$4.50M derived: sum of 3 quarters · filed 2026-08-05 | -$3.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$170.00K 10-Q · filed 2026-05-07 | -$2.78M derived: sum of 2 quarters · filed 2026-05-07 | -$1.44M derived: sum of 3 quarters · filed 2026-05-07 | -$4.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.27M derived: sum of 2 quarters · filed 2026-02-23 | -$4.65M derived: sum of 3 quarters · filed 2026-08-05 | $1.73M 10-K · filed 2026-02-23 |
| 2025-09-30 | $1.33M 10-Q · filed 2025-11-05 | -$2.05M derived: sum of 2 quarters · filed 2026-08-05 | $4.33M 10-Q · filed 2025-11-05 | $3.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$3.38M 10-Q · filed 2026-08-05 | $3.00M 10-Q · filed 2026-08-05 | $1.83M derived: sum of 3 quarters · filed 2026-08-05 | $2.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.38M 10-Q · filed 2026-05-07 | $5.21M derived: sum of 2 quarters · filed 2026-05-07 | $6.34M derived: sum of 3 quarters · filed 2026-05-07 | $6.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$42.00K derived: sum of 2 quarters · filed 2026-02-23 | $387.00K derived: sum of 3 quarters · filed 2026-02-23 | -$5.53M 10-K · filed 2026-02-23 |
| 2024-09-30 | $1.13M 10-Q · filed 2025-11-05 | $1.56M derived: sum of 2 quarters · filed 2025-11-05 | -$4.36M 10-Q · filed 2025-11-05 | -$5.35M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $429.00K 10-Q · filed 2025-08-06 | -$5.49M 10-Q · filed 2025-08-06 | -$6.48M derived: sum of 3 quarters · filed 2026-02-23 | -$9.19M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$5.92M 10-Q · filed 2025-05-08 | -$6.91M derived: sum of 2 quarters · filed 2026-02-23 | -$9.61M derived: sum of 3 quarters · filed 2026-02-23 | -$14.70M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$3.70M derived: sum of 2 quarters · filed 2026-02-23 | -$8.79M derived: sum of 3 quarters · filed 2026-02-23 | -$21.89M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$2.71M 10-Q · filed 2024-11-04 | -$7.79M derived: sum of 2 quarters · filed 2024-11-04 | -$20.90M 10-Q · filed 2024-11-04 | -$12.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$5.09M 10-Q · filed 2024-08-01 | -$18.19M 10-Q · filed 2024-08-01 | -$9.31M derived: sum of 3 quarters · filed 2025-02-27 | -$22.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$13.10M 10-Q · filed 2024-05-03 | -$4.22M derived: sum of 2 quarters · filed 2025-02-27 | -$17.81M derived: sum of 3 quarters · filed 2025-02-27 | -$29.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.71M derived: sum of 2 quarters · filed 2025-02-27 | -$16.10M derived: sum of 3 quarters · filed 2025-02-27 | -$111.14M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$13.59M 10-Q · filed 2023-11-03 | -$24.98M derived: sum of 2 quarters · filed 2023-11-03 | -$120.02M 10-Q · filed 2023-11-03 | -$146.04M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$11.39M 10-Q · filed 2023-08-04 | -$106.43M 10-Q · filed 2023-08-04 | -$132.45M derived: sum of 3 quarters · filed 2024-02-26 | $31.62M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$95.04M 10-Q · filed 2023-05-08 | -$121.06M derived: sum of 2 quarters · filed 2024-02-26 | $43.01M derived: sum of 3 quarters · filed 2024-02-26 | $43.01M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$26.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $138.05M derived: sum of 2 quarters · filed 2024-02-26 | $138.05M derived: sum of 3 quarters · filed 2024-02-26 | $138.05M 10-K · filed 2024-02-26 |
| 2021-09-30 | $164.07M 10-Q · filed 2022-11-03 | $164.07M derived: sum of 2 quarters · filed 2022-11-03 | $164.07M 10-Q · filed 2022-11-03 | $164.07M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |